Navigation Links
Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
Date:6/24/2008

LONDON, June 24 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has initiated a Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes Rhinocort(R) as the steroid comparator arm. The study is expected to be completed by the end of Q3 2008.

The study is designed to evaluate the safety, tolerability, and efficacy of intranasal MRX-4 in AR patients outside of the local allergy season as compared with both placebo and an intranasal steroid. An experimental multi-functional anti-inflammatory drug (MFAID), MRX-4 is a non-steroidal potential treatment for AR that has generated promising pre-clinical efficacy data. In a Phase I equivalent trial completed in Israel earlier this year, it was shown to be well tolerated with no clinical significant adverse effects.

"We are excited about the opportunity to evaluate the safety and efficacy of MRX-4 in a multi-dose trial for treating allergic rhinitis," said Mark Cohen, chairman of the board of Morria. "MRX-4 could provide unique, non-steroidal, first-choice drug treatment for allergic rhinitis."

According to Dr. Yuval Cohen, Morria's president, it is rare for a first-in-man efficacy study in AR (phase II) to include a steroid comparator arm. "Most companies prefer waiting until they have generated substantial clinical efficacy data comparing their drug to a placebo before venturing to compare it to a standard market treatment, such as a nasal corticosteroid. Our decision to include the steroid comparator arm so early in our clinical development is a combination of our confidence in MRX-4's performance as well as the creativity of our clinical team in streamlining and maximizing the efficacy of our clinical development program. We believe that
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
2. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
3. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
4. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
7. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... 2014   Mast Therapeutics, Inc. (NYSE ... that Santosh Vetticaden, Chief Medical Officer and Senior ... personal reasons, in mid-September.  Edwin L. Parsley ... Pharmaceuticals, which Mast acquired earlier this year, will ... interim Chief Medical Officer.  Dr. Parsley previously was ...
(Date:8/29/2014)... 2014 Research and Markets has ... Industry Report, 2014-2017" report to their offering. ... proportion of reimbursement for medical expenses, the Chinese orthopedic ... scale presenting a CAGR of 19.2% during 2009-2013. Trauma ... segments of orthopedic instruments in China ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... Asante Solutions, Inc. (Asante), a medical device company focused ... mark for its Pearl Insulin Pump, the only insulin ... mark is a European proof of conformity that certifies ... Asante has begun discussions with potential distribution partners in ...
... Neuralstem, Inc. (NYSE Amex: CUR ) announced ... Phase I safety trial of Neuralstem,s human spinal cord ... Lou Gehrig,s disease), and unpaid Neuralstem consultant, presented interim ... reported yesterday at the American Academy of Neurology (AAN ...
Cached Medicine Technology:Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump 2Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 2Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 3Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 4
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 Bringing ... Profit By Search announces the Labor Day discount ... clients will surely get the complete services related to ... SEO professionals, Content Writers, and others do have a ... perfection that reflects in their work and since the ...
(Date:8/30/2014)... "I had a handicapped friend who could not walk ... from Wetumpka, Ala. "In order to help her be able ... came up with a way for her to use her ... the patent-pending Deezers to allow crutches to be used on ... walkers, or canes at the beach. The device reduces the ...
(Date:8/30/2014)... Bethesda, MD (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) robs people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 One of the ... era is the gluten-free diet. Originally meant for sufferers of ... a catchall for people who are looking to get healthier ... not only is this kind of information erroneous, it also ... problems because of a drastic change in their food ...
Breaking Medicine News(10 mins):Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2
... 21 As the pace of global,competition ... research,groups to keep up. Effective market research ... customers, markets and competitors as,reference points to ... from benchmarking leader Best Practices, LLC., ...
... got easier and a lot more accessible to the public ... a ground-breaking partnership between a young British entrepreneur, a global ... , Debuted April 20 to offer individuals a meaningful way ... hope www.MalariaEngage.org will do for African research what ...
... Don,t eat for 2, because complications increase with excess weight, ... been considered a kind of gastronomical free-for-all. After all, ... food she eats, right? , The problem is, the ... and extra weight gain can increase the risk of pregnancy ...
... J. Deitsch, Chairman,and Chief Executive Officer of Nutra ... will be updating the investment,community through his personal ... dynamic profile will include exclusive interviews with,Rik J. ... his personal,stock watchlist, photos of company products and ...
... Sales force performance,significantly impacts growth and ... to effectively disseminate vital information to their ... to the overall success of,their companies., ... Excellence:,Resources, Structure and Processes to Optimize Pharmaceutical ...
... point to the brain-draining effects of decision-making , , FRIDAY, April ... flavors of ice cream, people,s lives are full of choices. ... sap your stamina, your ability to stay focused and even ... people faced with a variety of choices had more trouble ...
Cached Medicine News:Health News:Creating an Effective Market Research Group to Generate High-Impact Business Results 2Health News:International health experts to enlist the public in war on African malaria 2Health News:International health experts to enlist the public in war on African malaria 3Health News:International health experts to enlist the public in war on African malaria 4Health News:International health experts to enlist the public in war on African malaria 5Health News:International health experts to enlist the public in war on African malaria 6Health News:International health experts to enlist the public in war on African malaria 7Health News:International health experts to enlist the public in war on African malaria 8Health News:Extra Pounds During and Between Pregnancies Can Pose Problems 2Health News:Extra Pounds During and Between Pregnancies Can Pose Problems 3Health News:Rik Deitsch, CEO of Nutra Pharma Creates Personal Wall on WallSt.net's Financial Social Community, my.wallst.net 2Health News:Complementary Excerpt Available from Best Practices: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications 2Health News:Choices Sap Your Stamina, Self Control: Study 2Health News:Choices Sap Your Stamina, Self Control: Study 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: